Open company graph database — free web & API
ログイン

Nephron Pharmaceuticals Corporation

ネフロン製薬株式会社別名
銘柄コード
—
上場市場
—
国
United States of America
従業員(単独)
—
関連会社
1
§01

基本情報

BASIC
所在地
4500 12th Street Extension West Columbia, SC 29172
社長
従業員数(単独)
従業員数(連結)
開始日
終了日
§02

サイト

1 DOMAINS
§03

事業内容

3
Contract Manufacturing503B OutsourcingRespiratory Medication Production
§04

関連会社

1 COMPANIES
会社名 Group 親会社 子会社 得意先 仕入先 業務提携 銀行等 株主等
Roper St. Francis
得意先
リンク無しの社名は OpenBizGraph 未登録企業
§05

関連図

NETWORK
ドラッグで移動 · クリックで詳細へ
§06

沿革

70 EVENTS

Albuterol 0.083% Inhalation Solution ANDA approved出典

Applied for Albuterol 0.5% Inhalation Solution ANDA出典

Nephron expanded operations to 56,000 sq. ft.出典

Helping patients breathe easy出典

Alleviating respiratory discomfort出典

S2 Racepinephrine Inhalation Solution launched出典

Swift growth出典

Albuterol 0.5% Inhalation Solution ANDA approved出典

Ipratropium Bromide 0.02% Inhalation Solution ANDA approved出典

Expansion to 76,000 sq.ft.出典

Addition of single vial, bar coded packaging出典

Getting the word out出典

Lou Kennedy comes on board and begins to build marketing sales force出典

Amplifying production出典

Addition of 4 new Blow-Fill-Seal machines increased capacity to 58 million vials per month出典

A breath of fresh air出典

Albuterol 0.042% Inhalation Solution ANDA approved出典

Automation promotes accuracy出典

Launched the Electronic Fill Weights – EBR Manager出典

Keeping up with demand出典

Nephron acquires its first pieces of Bosch high-speed packaging machinery出典

Improving efficiency and speed出典

Ipratropium Bromide 0.5mg/ Albuterol Sulfate 3mg Inhalation Solution (DuoDose) ANDA approved出典

Addition of a High Speed Single Vial Packaging Line – 35,000 vials per hour出典

Advanced Processes and Quality Controls出典

A year of continued growth出典

Manufacturing Facility Expansion: Construction of an additional formulation weigh suite and filling suite出典

Addition of Rommelag BFS Machines to increase capacity by 18 million vials per month出典

Fighting for a level playing field出典

Bill Kennedy hearing before the US House of Representatives on H.R. 1706: Protecting Consumer Access to Generic Drugs Act of 2009出典

Expanding our reach出典

Albuterol 0.021% Inhalation Solution ANDA approved出典

Nephron expands distribution facilities with the purchase of a warehouse in Phoenix, AZ出典

Murray, KY warehouse expanded to 150,000 sq. ft.出典

A new economic driver for the Midlands出典

Nephron announced that the company would locate its new operations in Lexington County.出典

$313 million investment is expected to generate 707 new jobs.出典

Relief, now OTC出典

Sodium Chloride (hypertonic saline) 3% and 7% launched出典

Nephron SC breaks ground出典

Launch of our first OTC Medication Asthmanefrin出典

Efficiency through automation出典

The fabrication of the new palletizing systems for the lines at Nephron’s South Carolina facility completed出典

After 16 long months, Nephron finally receives full FDA approval出典

Budesonide 0.25mg and 0.5mg received ANDA approval出典

National launch of the Pocket Neb出典

Nephron 503B Outsourcing Facility officially launched出典

Became licensed in all 50 states出典

Released new opioid free alternatives出典

Established free overnight delivery via UPS出典

Reached a total of 900+ employees出典

Launched a $12.5 million expansion出典

Launched an educator program that employs over 860 local teachers出典

Reached a total of 2000+ FTE and PTE employees出典

Added 75,000 square feet of clean room manufacturing space出典

Installed 4 new sterile BFS lines出典

Nephron steps up to respond to COVID-19, seeking FDA approval to ramp up production出典

Opened a CLIA-certified Diagnostics Lab and began COVID-19 testing for employees, families and businesses in the Midlands and across South Carolina出典

Launched production of FDA approved hand sanitizer出典

Broke ground on a historic $215M expansion, including a vaccine production facility出典

Announced plans for a Kennedy Innovation Complex出典

Received FDA approval of an Abbreviated New Drug Application (ANDA) for two new products – 0.9% Sodium Chloride IV Bags, and Ketorolac Tromethamine Injection Vials出典

With the launch of Nephron Nitrile, a glove manufacturing venture, Nephron begins a $100 million construction project, adding a new 400,000 square-foot facility to its campus of existing facilities and hiring 250 new workers in the process出典

Continued combating the scourge of the COVID-19 pandemic by producing testing chemicals known as reagents, as well as the test kits themselves出典

Partnered with Dominion Energy to open the Nephron Clinical Lab–a way to support Midlands-area residents with fast, reliable COVID-19 vaccination and testing services出典

Developed a new wing of existing Nephron facilities where manufacturers can focus on the creation of life-saving antibiotics and chemotherapy drugs出典

Announced a new syringe and equipment manufacturing venture, Inject EZ出典

Partnered with the ISPE Foundation to launch a new internship program, which aims to diversify Nephron’s ever-growing employee base出典

Nephron 503B launched a new, innovative syringe presentation – the Cyclic Olefin Copolymer (COC) syringe出典

Owner and CEO Lou Kennedy received a National Manufacturing Icon Award from the National Association of Manufacturers (NAM)出典

§07

ニュース

13 ARTICLES

Julie Rameas Named 2026 Top Women Leader出典

Julie Rameas, Chief Procurement Officer at Nephron Pharmaceuticals, was named to The Healthcare Technology Report’s 2026 Top Women Leaders in Biotech and Life Sciences list. She joined Nephron in July 2023 and manages strategic sourcing and procurement for the company’s West Columbia, South Carolina campus. The report highlighted her extensive global procurement experience as a key contribution to Nephron’s operations.

NRx Pharma Gets FDA Approval for Ketamine出典

NRx Pharmaceuticals received FDA approval for its preservative‑free ketamine on October 30, 2026. The drug will be manufactured at Nephron’s West Columbia, South Carolina campus. The approval was announced in a press release by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP).

Nephron Announces CEO Transition出典

Nephron announced that Lou Kennedy is departing as CEO and that Haywood Miller has been appointed Interim CEO, effective immediately. The company said it remains focused on its transformation strategy and growth priorities, and enters this next chapter with the support of its secured lenders.

Nephron Pharmaceuticals Recognized in 2025 RXinsider Pharmacy500出典

Nephron Pharmaceuticals has been named to the 2025 Pharmacy500 list by RxInsider, recognizing its influence in the pharmacy supply chain. This is the second consecutive year the company has received this honor. The recognition highlights the company's commitment to providing access to safe and effective medications.

Nephron Pharmaceuticals Announces Key Leadership Appointments出典

Nephron Pharmaceuticals announced several key appointments to strengthen its leadership team. The new executives include a Chief Operating Officer and an Executive Vice President of Quality Systems.

Nephron Pharmaceuticals Invests $10M in BFS Capacity出典

Nephron Pharmaceuticals announced a $10 million investment to expand its BFS manufacturing capacity with a new production line. The first product will be BFS IV bottles to address FDA drug shortages. This expansion will improve efficiency and reduce costs for medication production.

Nephron Pharmaceuticals Recognized in 2024 RXinsider Pharmacy500出典

Nephron Pharmaceuticals Corporation was recognized in the 2024 RXinsider Pharmacy500 list, which honors the top 500 supply chain companies impacting the U.S. dispensing pharmacy industry. CEO Lou Kennedy expressed pride in the recognition and highlighted the company's commitment to quality, transformation, and trust.

NRx Pharmaceuticals and Nephron Pharmaceuticals Sign Co-Development Agreement出典

NRx Pharmaceuticals and Nephron Pharmaceuticals agreed to develop an intravenous ketamine product designed to prevent self-injection and abuse. They are targeting a launch in November 2024, pending FDA approval.

Nephron Pharmaceuticals Announces Six Key Executive Hires出典

Nephron Pharmaceuticals Corporation announced the hiring of six key executives, including roles in accounting, quality, and operations. The company highlighted the industry experience of the new hires and expressed pride in their team expansion.

Nephron raises $350M for growth with BlackRock and PNC出典

Nephron Pharmaceuticals announced a successful $350 million capital raise, led by BlackRock and PNC, to support its future growth. The funding aims to enhance the company's manufacturing capabilities and expand its impact in the pharmaceutical industry. Nephron is known for creating jobs in South Carolina and providing medications nationwide.

§09

出典・更新

SOURCES
↑